Day: March 22, 2024

TORONTO, March 22, 2024 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) has completed its previously announced offering of US$1,000,000,000 in aggregate principal amount of 6.350% senior notes due 2054 (the “Notes”). In connection with the closing of the offering, Fairfax entered into a customary registration rights agreement. Fairfax intends to use the net proceeds of this offering for general corporate purposes. The offering was made solely by means of a private placement either to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or to certain non-U.S. persons in offshore transactions pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act and the Notes may...

MONACO, March 22, 2024 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers” or the “Company”) announced today that its Annual Report on Form 20-F for the year ended December 31, 2023 has been filed with the Securities and Exchange Commission and can be accessed on the Company’s website www.scorpiotankers.com in the Investors section under Reports and Presentations. Shareholders may also request a hard copy of the Annual Report, which includes the Company’s complete 2023 audited financial statements, free of charge, by contacting the Company at: Scorpio Tankers Inc.Attn: Investor Relations150 E 58th StreetNew York, NY 10155Tel: +1-212-542-1616E-mail: investor.relations@scorpiotankers.com Reports and other information regarding the Company are also available without charge at a website maintained by the U.S. Securities...

Nutra Pharma Corp. has reached a bifurcated settlement with the SEC along with its CEO and a Consultant to the company CORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) — Nutra Pharma Corporation (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) earlier this week. On March 19, 2024, the United States District Court for the Eastern District of New York in SEC v. Nutra Pharma Corporation, Erik Deitsch a/k/a Rik Deitsch, and Sean Peter McManus, Case No. 1:18-cv-05459-JS (E.D.N.Y.), approved bifurcated settlements in the form of consent judgments (the “Consent Judgments”) entered by the Court, wherein the Defendants, without admitting or denying the allegations of the Complaint except as to personal and subject matter jurisdiction, resolved all liability...

Sysco President and CEO Kevin Hourican announced the generous donation at a news conference with Louisville Mayor Craig Greenberg and Louisville Fire Chief Brian O’Neill LOUISVILLE, Ky., March 22, 2024 (GLOBE NEWSWIRE) — Today, Sysco President and CEO Kevin Hourican announced Sysco Corporation (NYSE:SYY), the leading global foodservice distribution company, had filled two Louisville firehouse pantries and donated $20,000 toward their annual award banquet in a gesture of thanks for their heroic bridge rescue of a Sysco delivery partner.    Louisville Mayor Craig Greenberg and Louisville Fire Chief Brian O’Neill joined Hourican to honor the firefighters and first responders who on March 1 rescued a Sysco driver whose truck was hanging precariously over the Ohio River from the Clark Memorial Bridge. Firefighter Bryce Carden repelled...

BROSSARD, Quebec, March 22, 2024 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a second and final tranche of 650,000 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $182,000, of a non-brokered private placement initially announced on February 27, 2024 (“Private Placement”). Combined with the first closing announced on February 27, 2024, the aggregate number of Units is 2,064,286 and the aggregate gross proceeds amount to $578,000.08. Each Unit consists of: – One (1) common share (“Share”), and – One (1) common share warrant (“Warrant”). As part of the closing of the second and final tranche...

Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and thirty thousand (USD 130,000) by issuing thirteen million (13,000,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 15.98 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement. Following the above-mentioned transactions, the subsidiary will hold 23.160.596 shares in the Company, or around 7.7% of issued shares, and the number of issued shares has increased from 289,727,462 to 302,727,462 shares as a result thereof. On 26 February 2024,...

REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and thirty thousand (USD 130,000) by issuing thirteen million (13,000,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 15.98 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement. Following the above-mentioned transactions, the subsidiary will hold 23,160,596 shares in the Company, or around 7.7% of issued shares, and the number of issued shares has increased from 289,727,462...

TORONTO, March 22, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR; OTCQB: BHLL) announces that it has elected to issue an aggregate of 6,398,439 shares of common stock of the Company (the “Interest Shares”) to certain holders of 7.5% convertible debentures (the “Series 1 Convertible Debentures”) and 10.5% convertible debentures (the “Series 2 Convertible Debentures” and, together with the Series 1 Convertible Debentures, the “Convertible Debentures”) in full satisfaction of the interest payable thereunder as of March 31, 2024 in the aggregate amount of USD$511,875.00 (the “Interest Payment”). The Convertible Debentures mature on March 31, 2026. In accordance with the terms of the Convertible Debentures, the Company will issue the Interest Shares at a price of USD$0.08 per Interest...